Danaher (NYSE:DHR) Earns Buy Rating from Analysts at Guggenheim

Research analysts at Guggenheim started coverage on shares of Danaher (NYSE:DHR) in a research note issued on Thursday, MarketBeat.com reports. The firm set a “buy” rating and a $275.00 price target on the conglomerate’s stock. Guggenheim’s price objective would suggest a potential upside of 20.46% from the stock’s current price.

Several other equities analysts also recently issued reports on the company. Evercore ISI boosted their price objective on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. TD Cowen raised their price target on Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a report on Wednesday, October 23rd. Robert W. Baird reduced their price objective on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, December 14th. Finally, Wells Fargo & Company assumed coverage on shares of Danaher in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price objective for the company. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $287.30.

Danaher Price Performance

Shares of DHR opened at $228.30 on Thursday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The company has a market cap of $164.90 billion, a P/E ratio of 43.57, a PEG ratio of 4.33 and a beta of 0.83. Danaher has a 12 month low of $222.53 and a 12 month high of $281.70. The stock has a fifty day moving average price of $244.71 and a 200 day moving average price of $256.93.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter last year, the company earned $2.02 EPS. The company’s revenue for the quarter was up 3.1% compared to the same quarter last year. On average, research analysts forecast that Danaher will post 7.5 earnings per share for the current year.

Institutional Trading of Danaher

A number of hedge funds have recently bought and sold shares of DHR. Benjamin Edwards Inc. lifted its position in shares of Danaher by 1.8% in the 2nd quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock valued at $538,000 after acquiring an additional 38 shares in the last quarter. Wedge Capital Management L L P NC lifted its holdings in shares of Danaher by 3.2% in the third quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock valued at $342,000 after purchasing an additional 38 shares in the last quarter. Abacus Planning Group Inc. boosted its position in shares of Danaher by 0.7% in the second quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock worth $1,359,000 after buying an additional 40 shares during the period. Certified Advisory Corp grew its holdings in shares of Danaher by 4.5% during the second quarter. Certified Advisory Corp now owns 926 shares of the conglomerate’s stock valued at $231,000 after buying an additional 40 shares in the last quarter. Finally, Meridian Financial Partners LLC lifted its stake in Danaher by 4.4% in the 3rd quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock worth $266,000 after acquiring an additional 40 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.